Logo

Jeffrey Edwards, Arnold Pinkston, Gregory Hinckley

May 11, 2017

Bio-Rad has elected three new board members — Jeffrey Edwards, Gregory Hinckley, and Arnold Pinkston — at its annual shareholders meeting. 

Jeffrey Edwards previously served as CEO of Allergan from 2005 to August 2014, and retired from the company in 2015 after 22 years. 

Arnold Pinkston previously served as executive vice president and general counsel for Allergan, senior vice president and general counsel for Beckman Coulter, and vice president and deputy general counsel at Eli Lilly.

Gregory Hinckley currently serves as president of Mentor Graphics, a supplier of products and services used for the design of electronic content, and has 30 years of public company experience.

The newly-elected members replace Louis Drapeau, Robert Malchione, Joel McComb and Deborah Neff, who declined to stand for reelection due to disagreements with Bio-Rad's management regarding executive personnel and corporate governance matters, according to a Securities and Exchange Commission filing. In a statement, Bio-Rad noted that their decision not to stand for reelection was not related to any issues regarding the integrity of the company's financial statements or accounting policies and practices.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.